IntelGenx Receives Health Canada Clearance to Begin Phase 2a Study with Montelukast Versafilm(TM) in Mild to Moderate Alzheimer's Disease
SAINT-LAURENT, QUEBEC–(Marketwired – Dec. 15, 2017) – IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the “Company” or “IntelGenx”) is pleased to announce [...]